Antibody-Drug Conjugate (ADC) — Pharmacokinetics Comparison
Side-by-side comparison of 11 Antibody-Drug Conjugate (ADC) drugs with interactive PK simulators. Compare dosing, routes of administration, indications, and pharmacokinetic profiles.
| Drug | Route | Model Type | Indication | Therapeutic Area | Simulator |
|---|---|---|---|---|---|
| ADCs | IV Infusion | Population PK | HER2-positive breast cancer, NSCLC, gastric/GEJ cancer | Oncology | Open → |
| Dato | — | Population PK | TROP2-positive metastatic breast cancer | Oncology | Open → |
| Datroway | IV Infusion | Population PK (2-CMT ADC parallel linear+MM + 1-CMT Payload) | Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload | Oncology | Open → |
| Enhertu | IV Infusion | Population PK (Sequential 2-CMT ADC + 1-CMT Payload) | HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC | Oncology | Open → |
| Mirvetuximab Soravtansine (ELAHERE) | IV Infusion | Population PK (2-CMT ADC + 1-CMT DM4 Payload) | FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer; maytansinoid DM4 payload | Oncology / Ovarian Cancer | Open → |
| PBPK-PD Topo1-Based ADC | Intravenous | PBPK-PD Model | Solid tumors (breast, lung, gastric, colorectal cancer) | Oncology | Open → |
| PBPK-PD Topo1-Based ADC | Intravenous | PBPK-PD Model | Solid tumors (breast, lung, gastric, colorectal cancer) | Oncology | Open → |
| PBPK-PD of ADCs | — | — | — | Oncology | Open → |
| Patritumab Deruxtecan (HER3-DXd) | IV Infusion | Population PK (2-CMT ADC + 1-CMT DXd Payload) | EGFR-mutant NSCLC after EGFR TKI and platinum therapy; HER3-directed ADC with DXd payload | Oncology / NSCLC | Open → |
| T-DXd (Enhertu) PBPK-PD ILD Risk | IV Infusion | PBPK-PD | HER2-positive metastatic breast cancer, gastric/GEJ adenocarcinoma, NSCLC, and other HER2-expressing solid tumors; ILD risk stratification and dose optimization | Oncology / Breast Cancer | Open → |
| Trodelvy | IV Infusion | Population PK (Triple-analyte: ADC + SN-38 payload + total antibody) | Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload | Oncology | Open → |
Individual Drug Profiles
ADCs
- Route
- IV Infusion
- Model Type
- Population PK
- Indication
- HER2-positive breast cancer, NSCLC, gastric/GEJ cancer
- Therapeutic Area
- Oncology
Dato
- Route
- N/A
- Model Type
- Population PK
- Indication
- TROP2-positive metastatic breast cancer
- Therapeutic Area
- Oncology
Datroway
- Route
- IV Infusion
- Model Type
- Population PK (2-CMT ADC parallel linear+MM + 1-CMT Payload)
- Indication
- Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload
- Therapeutic Area
- Oncology
Enhertu
- Route
- IV Infusion
- Model Type
- Population PK (Sequential 2-CMT ADC + 1-CMT Payload)
- Indication
- HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC
- Therapeutic Area
- Oncology
Mirvetuximab Soravtansine (ELAHERE)
- Route
- IV Infusion
- Model Type
- Population PK (2-CMT ADC + 1-CMT DM4 Payload)
- Indication
- FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer; maytansinoid DM4 payload
- Therapeutic Area
- Oncology / Ovarian Cancer
PBPK-PD Topo1-Based ADC
- Route
- Intravenous
- Model Type
- PBPK-PD Model
- Indication
- Solid tumors (breast, lung, gastric, colorectal cancer)
- Therapeutic Area
- Oncology
PBPK-PD Topo1-Based ADC
- Route
- Intravenous
- Model Type
- PBPK-PD Model
- Indication
- Solid tumors (breast, lung, gastric, colorectal cancer)
- Therapeutic Area
- Oncology
Patritumab Deruxtecan (HER3-DXd)
- Route
- IV Infusion
- Model Type
- Population PK (2-CMT ADC + 1-CMT DXd Payload)
- Indication
- EGFR-mutant NSCLC after EGFR TKI and platinum therapy; HER3-directed ADC with DXd payload
- Therapeutic Area
- Oncology / NSCLC
T-DXd (Enhertu) PBPK-PD ILD Risk
- Route
- IV Infusion
- Model Type
- PBPK-PD
- Indication
- HER2-positive metastatic breast cancer, gastric/GEJ adenocarcinoma, NSCLC, and other HER2-expressing solid tumors; ILD risk stratification and dose optimization
- Therapeutic Area
- Oncology / Breast Cancer
Trodelvy
- Route
- IV Infusion
- Model Type
- Population PK (Triple-analyte: ADC + SN-38 payload + total antibody)
- Indication
- Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload
- Therapeutic Area
- Oncology
Key Differences
Routes of Administration
IV InfusionIntravenous
Therapeutic Areas
OncologyOncology / Ovarian CancerOncology / NSCLCOncology / Breast Cancer
Indications
- • HER2-positive breast cancer, NSCLC, gastric/GEJ cancer
- • TROP2-positive metastatic breast cancer
- • Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload
- • HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC
- • FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer; maytansinoid DM4 payload
- • Solid tumors (breast, lung, gastric, colorectal cancer)
- • EGFR-mutant NSCLC after EGFR TKI and platinum therapy; HER3-directed ADC with DXd payload
- • HER2-positive metastatic breast cancer, gastric/GEJ adenocarcinoma, NSCLC, and other HER2-expressing solid tumors; ILD risk stratification and dose optimization
- • Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload
Disclaimer: This comparison is for educational and research purposes only. Pharmacokinetic parameters are derived from published population PK models and may not reflect individual patient variability. Drug selection and dosing should always be guided by clinical judgment, prescribing information, and applicable guidelines. Not intended for clinical use.